Adding too many venoms to produce a polyvenon can be a good manufacturing strategy but it's clinical efficiency and efficacy still need to be studied well. It surely require to use more ASV vials of polyvenon in comparison to monovalent or divalent ASVs to achieve complete recovery thus evasing more quantities of foreign protein of equine origin with all risks of adverse action besides it's life saving. We have little data about any late reaction of such big quantities of ASV we introduce in shape of such polyvenons. We don't know exactly what happens after six months or after a year with patients treated with multiple vials of ASV.